A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia (Blood, 2021)

(untitled) - Vyas, P; Daver, N; Chao, M; Xing, G; Renard, C; Ramsingh, G; Wei, AH; Sallman, DA